Polycystic Ovary Syndrome (PCOS), a common endocrine disorder affecting women, is undergoing a significant renaming to Polycystic Metabolic Ovarian Syndrome (PMOS). This proposed change aims to underscore the condition's substantial metabolic component, which often contributes to long-term health complications beyond reproductive issues. The shift in nomenclature reflects a growing understanding among medical professionals of the systemic nature of the syndrome, moving beyond a sole focus on ovarian function.
PMOS is estimated to affect between 5% and 10% of women of reproductive age in the UK, making it one of the most prevalent hormonal disorders. Despite its widespread impact, many women report significant delays in diagnosis and a general lack of public awareness. Symptoms can vary widely but commonly include irregular periods, excess androgen (leading to symptoms like hirsutism and acne), and the presence of polycystic ovaries on ultrasound. Insulin resistance, a key metabolic feature, affects a substantial proportion of women with PMOS and increases the risk of developing type 2 diabetes and cardiovascular disease.
The current diagnostic criteria, often referred to as the Rotterdam criteria, require at least two of the three main symptoms: oligo- or anovulation, clinical or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound, after the exclusion of other aetiologies. However, the multifaceted nature of PMOS means that not all women present with all symptoms, complicating diagnosis. Research indicates that the average time from symptom onset to diagnosis can be several years, during which women may experience significant distress and a worsening of symptoms.
Experts believe that the new name, PMOS, will help to reframe the condition, encouraging a more holistic approach to diagnosis and management. By explicitly including 'Metabolic', it is hoped that healthcare professionals will be prompted to routinely screen for metabolic markers such as blood glucose levels, lipid profiles, and blood pressure, even in younger patients. This could lead to earlier interventions for conditions like insulin resistance and reduce the long-term risk of associated health problems.
The implications for research are also significant. A greater emphasis on the metabolic aspects of PMOS could stimulate further studies into the underlying mechanisms of the syndrome and the development of more targeted therapies. Currently, management strategies often involve lifestyle modifications, hormonal contraceptives for menstrual regulation and androgen reduction, and metformin for insulin sensitisation. A deeper understanding of the metabolic pathways could pave the way for novel pharmacological treatments.
However, the renaming alone will not solve the persistent issue of low awareness and understanding. Advocacy groups and medical charities continue to call for increased funding for PMOS research, improved training for healthcare professionals, and public health campaigns to educate both patients and the wider community about the condition. Raising the profile of PMOS is crucial to ensure that women receive timely diagnosis, appropriate care, and the support they need to manage this complex lifelong condition effectively.
Source: Endocrine Society, NHS England